Proton International, a proton therapy technology developer, received $30 million in financing
Release date: 2017-04-10 Source: 36 æ°ª Autoclave Products,Vertical Autoclave,Lab Verticcal Autoclave,Lab Animal Transfer Station Guangdong Widinlsa International Co.Ltd , https://www.widinlsa.com
ProTom International, a proton therapy technology developer, recently announced that it has raised $30 million in a new round of funding, which will be completed by the end of June 2017. As of the end of March, $10 million has been received.
Founded in 2008, ProTom is an advanced cancer treatment technology company specializing in the development of proton therapy with the vision of making proton therapy affordable and suitable for small communities. ProTom produces the Radiance 330 Proton Therapy System, which is designed to provide focused proton therapy for cancer patients. The company said that the Massachusetts General Hospital is expected to install a Radiance 330 system, which is expected to be operational by the end of 2017.
Proton therapy uses a controlled proton beam to kill cancer cells while minimizing damage to normal tissue. Proton beam therapy is one of the most sophisticated and accurate radiation treatments for a variety of tumors and is suitable for a wide range of tumors. As early as more than 50 years ago, the first patient in the world received proton therapy. In 1988, the US Food and Drug Administration (FDA) approved proton therapy as a radiotherapy for clinical treatment of patients.
ProTom's Radiance 330 is equipped with ProTom's Fidelity beam scanning system, which is innovatively designed and optimized for discrete scanning. This type of scan accurately "locates" the tumor and uses magnetic transduction to accurately direct lateral dose deposition and beam energy changes in accordance with the proton dose prescribed by the physician, which can be controlled with sub-millimeter precision in one second to control wear. Through depth. This highly sophisticated 3D beam scanning technology allows physicians to take advantage of the proton's dose control advantages to their full potential, even in the most complex situations.
Michaelsonson, managing partner of Michaelson Capital Partners, said: "ProTom's Radiance 33 is a disruptive technology that significantly reduces the cost of treatment for proton therapy while improving the quality of life and quality of life of patients. Since we were in 2015 8 Since the acquisition of the company in the month, ProTom's progress has been amazing."
“ProTom continues to demonstrate that the Radiance 330 is the next generation solution for advanced proton therapy for cancer patients. ProTom CEO Steve Spotts said it expects to expand the use of this technology in Asian countries and the United States.